Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsPreventive Cancer ScreeningDiffuse Large B-Cell Lymphoma (DLBCL): Polatuzumab-R-CHP vs. Standard R-CHOP and CAR-T Cell Rescue Pathways
Preventive Cancer Screening

Diffuse Large B-Cell Lymphoma (DLBCL): Polatuzumab-R-CHP vs. Standard R-CHOP and CAR-T Cell Rescue Pathways

11 min read
Sep 2, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #120

Clinical Summary & Key Takeaways

A cutting-edge clinical hematologic oncology review on Diffuse Large B-Cell Lymphoma (DLBCL), cell-of-origin subtyping (GCB vs ABC/non-GCB), POLARIX trial data (Polatuzumab Vedotin + R-CHP), double-hit lymphoma genomics (MYC/BCL2), and second-line CAR-T cell immunotherapies.

CRITICAL CLINICAL RED FLAG: Painless, rubbery, rapidly enlarging lymph node swelling in the neck, armpit, or groin accompanied by systemic "B-symptoms" (unexplained fevers >38°C, drenching night sweats, and involuntary weight loss >10% over 6 months) requires immediate excisional lymph node biopsy.

1. Classification & Biology: The Cell-of-Origin Framework

DLBCL is the most common aggressive non-Hodgkin lymphoma. Hans algorithm immunohistochemistry and gene expression profiling stratify DLBCL into two distinct biological subtypes:

  • Germinal Center B-Cell-like (GCB): Better prognosis with standard immunochemotherapy.

  • Activated B-Cell-like (ABC / Non-GCB): Driven by constitutive NF-kappaB pathway activation, traditionally associated with higher relapse rates.

  • Double-Hit / Triple-Hit Lymphomas: Harbor concurrent rearrangements of MYC and BCL2 and/or BCL6, requiring dose-adjusted EPOCH-R regimens.

2. Frontline Systemic Breakthrough: The POLARIX Trial

For over 20 years, R-CHOP was the undisputed standard of care. The POLARIX phase III trial demonstrated that replacing vincristine with Polatuzumab Vedotin (an anti-CD79b Antibody-Drug Conjugate delivering the microtubule disruptor MMAE):

  1. Pola-R-CHP: Polatuzumab Vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone.

  2. Progression-Free Survival Advantage: Significantly reduced the risk of disease progression, relapse, or death by 27% in IPI 2-5 intermediate/high-risk patients.

  3. Complete Response: Confirmed on end-of-treatment 18F-FDG PET-CT (Deauville score 1-3).

"DLBCL is a potentially curable blood cancer. Incorporating CD79b antibody-drug conjugates upfront and CAR-T cell therapy for relapsed disease provides renewed hope for long-term remission." — Dr. Neha Gupta
Spica Healthcare Clinical & Surgical Protocol Illustration #120
Spica Healthcare Clinical & Surgical Protocol Illustration #120

3. Relapsed/Refractory Disease: CAR-T Cell Revolution

For patients relapsing within 12 months of frontline therapy, autologous anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapies (Axicabtagene Ciloleucel, Tisagenlecleucel, Lisocabtagene Maraleucel) achieve durable remissions in 40–50% of refractory patients (ZUMA-7 / TRANSFORM trials).

CLINICAL CAUTION: Fine Needle Aspiration (FNAC) is strictly inadequate for lymphoma diagnosis; formal excisional or core needle biopsy with flow cytometry and immunohistochemistry is mandatory for accurate subtyping.

4. Bispecific Antibodies: Off-the-Shelf Rescue

CD20xCD3 T-cell engaging bispecific antibodies (Glofitamab, Epcoritamab) recruit host T-cells directly to destroy CD20-expressing lymphoma cells, providing an effective off-the-shelf inpatient option.

5. Peer-Reviewed References & Clinical Guidelines

1. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma (POLARIX) — NEJM, 2022; 386: 351-363.

2. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7) — NEJM, 2022; 386: 640-654.

Frequently Asked Patient Questions

Limb Salvage with modular titanium megaprosthesis removes the tumor completely while preserving the limb, allowing patients to walk, work, and maintain full social independence without the physical disability of an artificial limb.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director — Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.